GenKyoTex reports progress of Setanaxib phase 2 investigator initiated trials
- Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand
- 13 patients have completed full 48-week treatment in DKD trial; no safety signals identified
- Phase 2 IPF trial funded by NIH; poised to initiate patient enrollment following recently received FDA and IRB approvals
Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, announces today further progress in two investigator-initiated Phase II trials of setanaxib in diabetic kidney disease (DKD) and idiopathic pulmonary fibrosis (IPF).
For more information,